At the time of writing, Ionis Pharmaceuticals Inc [IONS] stock is trading at $74.17, up 3.19%. An important factor to consider is whether the stock is rising or falling in short-term value. The IONS shares have gain 3.73% over the last week, with a monthly amount glided 12.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on October 08, 2025, when JP Morgan upgraded its rating to a Overweight but kept the price target unchanged to $80 for it. Previously, Goldman upgraded its rating to Neutral on September 26, 2025, and kept the price target unchanged to $65. On September 03, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $70 on the stock. Morgan Stanley upgraded its rating to a Overweight but stick to its price target of $62 on July 31, 2025. Barclays upgraded its rating to a Overweight but $57 remained the price target by the analyst firm on July 01, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on April 07, 2025, and assigned it a price target of $45. In a note dated March 31, 2025, Redburn Atlantic initiated an Neutral rating and provided a target price of $39 on this stock.
For the past year, the stock price of Ionis Pharmaceuticals Inc fluctuated between $23.95 and $74.42. Currently, Wall Street analysts expect the stock to reach $84.42 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $74.17 at the most recent close of the market. An investor can expect a potential return of 13.82% based on the average IONS price forecast.
Analyzing the IONS fundamentals
According to Ionis Pharmaceuticals Inc [NASDAQ:IONS], the company’s sales were 967.66M for trailing twelve months, which represents an 17.33% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.29%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.44 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 72.32 points at the first support level, and at 70.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.36, and for the 2nd resistance point, it is at 76.55.
Ratios To Look Out For
It is important to note that Ionis Pharmaceuticals Inc [NASDAQ:IONS] has a current ratio of 2.79. On the other hand, the Quick Ratio is 2.86, and the Cash Ratio is 0.37. Considering the valuation of this stock, the price to sales ratio is 12.42, the price to book ratio is 18.69.
Transactions by insiders
Recent insider trading involved Joseph Wender, Director, that happened on Oct 30 ’25 when 33600.0 shares were purchased. EVP Research, Swayze Eric completed a deal on Oct 16 ’25 to sell 53.0 shares. Meanwhile, Director PARSHALL B LYNNE sold 5000.0 shares on Oct 15 ’25.
